Affiliation:
1. Cleveland Clinic Foundation Department of Internal Medicine Cleveland Ohio USA
2. Clevleand Clinic Foundation Department of Pharmacy Cleveland Ohio USA
3. Cleveland Clinic Foundation Department of Pulmonary Medicine Cleveland Ohio USA
4. Cleveland Clinic Foundation Department of Infectious Disesaes Cleveland Ohio USA
Abstract
AbstractBackgroundMultidrug‐resistant organisms are increasing and are a significant cause of mortality among lung transplant recipients (LTRs). To assist with this issue, novel pharmacotherapies are being developed. This study describes the utilization of a novel antibiotic, cefiderocol (FDC), in LTRs where limited data exists in the current literature. We primarily assessed the clinical indications, duration of therapy, resistance, and adverse effects.MethodsConducted as a single‐center retrospective review, this study included adult LTRs who received FDC for at least 24 h. Data, extracted from electronic medical records, encompassed patient demographics, transplant history, antimicrobial dosing, adverse effects, bacterial cultures, and outcomes. The research protocol received institutional review board approval.ResultsFDC exhibited effectiveness against multidrug‐resistant Pseudomonas aeruginosa, with 26% 30‐day mortality and microbiological clearance observed in nine out of 13 cases. Notably, FDC was used in diverse clinical settings, including for prophylaxis, empiric, and targeted treatment.ConclusionFurther studies are needed to evaluate optimal clinical indications for FDC use in LTRs.
image